Osaka, Japan-based company opened first U.S. base of operations in October in Seattle under the managing directorship of Tsuenhiro Komatsabura. Ono already holds a significant equity investment in and supplies research funds to San Diego-based Telios Pharmaceuticals.
You may also be interested in...
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.
The market for devices to monitor and treat sleep apnea and its complications is set to grow by 7.3% annually in the next three years, with the US market expanding by 7.6% per year, according to the Meddevicetracker Dashboard.